Summit Therapeutics enters ivonescimab trial collaboration with ECOG-ACRIN
The Phase II/III study evaluates ivonescimab, an investigational bispecific antibody, in first-line biliary tract cancer.
GetSignal Summit Therapeutics Inc. SMMT
Summit Therapeutics announced on October 21, 2026, a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer.
Key facts
- Announced
- October 21, 2026
- Collaborator
- ECOG-ACRIN Cancer Research Group
- Drug
- Ivonescimab, an investigational bispecific antibody
- Indication
- First-line biliary tract cancer
Source: The company's release on Business Wire, October 21, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
